Scroll Top
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Related Posts
Gain Therapeutics’ SEE-Tx™ Platform Shows Increasing Evidence in Treating Diseases Caused by Protein Misfolding
Benzinga
Related Posts
Post navigation
Previous Post
Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference
Next Post
Small Molecules, STARs Treat Cell Models of GBA1-linked Parkinson’s
Latest Articles
Clear Filters
September 19, 2022
Gain Therapeutics Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson’s Disease
Read More
January 4, 2024
POWER OF SUPERCOMPUTING AND AI: REVOLUTIONIZING ALLOSTERIC DRUG DISCOVERY
Read More
August 29, 2023
Oral therapy GT-02287 shows promise in Parkinson’s mice models
Read More
Close
